2019
Patients With Opioid Use Disorder Deserve Trained Providers.
Weimer MB, Tetrault JM, Fiellin DA. Patients With Opioid Use Disorder Deserve Trained Providers. Annals Of Internal Medicine 2019, 171: 931-932. PMID: 31766053, DOI: 10.7326/m19-2303.Commentaries, Editorials and LettersInfluence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial
Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, Tetrault JM, Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology 2019, 45: 319-326. PMID: 31590179, PMCID: PMC6901445, DOI: 10.1038/s41386-019-0536-z.Peer-Reviewed Original ResearchConceptsAlcohol drinking behaviorFirst treatment periodTreatment periodNumber of drinksCrossover trialDrinking behaviorEfficacy of naltrexoneOpioid antagonist naltrexoneNMDA antagonist memantinePositive family historyDay treatment periodSelf-administration periodAlcohol-induced stimulationAd lib accessMemantine treatmentAntagonist naltrexoneOpioid systemFamily historyNTXPriming drinkMemantineNaltrexoneAlcohol cravingHeavy drinkersAlcohol dependenceThe Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortex
2018
Office-Based Addiction Treatment in Primary Care Approaches That Work
Edelman EJ, Oldfield BJ, Tetrault JM. Office-Based Addiction Treatment in Primary Care Approaches That Work. Medical Clinics Of North America 2018, 102: 635-652. PMID: 29933820, DOI: 10.1016/j.mcna.2018.02.007.Peer-Reviewed Original ResearchConceptsPrimary careUse disordersPrimary care-based approachSubstance useHuman immunodeficiency virusOpioid use disorderEvidence-based treatmentsCounseling-based interventionsSubstance use disordersImmunodeficiency virusSpecialty settingsMultidisciplinary teamCare-based approachHealth disparitiesAddiction treatmentCareDisordersOptimal approachImportant settingTreatmentPharmacotherapySetting
2016
Caring for patients with opioid use disorder in the hospitalCaring for patients with opioid use disorder in the hospital
Donroe JH, Holt SR, Tetrault JM. Caring for patients with opioid use disorder in the hospitalCaring for patients with opioid use disorder in the hospital. Canadian Medical Association Journal 2016, 188: cmaj.160290. PMID: 27647616, PMCID: PMC5135493, DOI: 10.1503/cmaj.160290.Peer-Reviewed Original Research
2015
Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review.
Tetrault JM, Butner JL. Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review. The Yale Journal Of Biology And Medicine 2015, 88: 227-33. PMID: 26339205, PMCID: PMC4553642.Peer-Reviewed Original ResearchConceptsPrescription opioid use disorderOpioid use disorderNon-medical useUse disordersPrescription opioidsMedical prescription opioid usePrescription opioid useOpioid useTreatment optionsHeroin useEpidemic proportionsPotential progressionDrug useRelated stigmaMedical communityDisordersDevastating consequencesOpioidsUnited StatesReview articleUnanswered questionsNational effortsEpidemiologyProgression
2013
2013 Update in addiction medicine for the generalist
Gordon AJ, Bertholet N, McNeely J, Starrels JL, Tetrault JM, Walley AY. 2013 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice 2013, 8: 18. PMID: 24499640, PMCID: PMC3819258, DOI: 10.1186/1940-0640-8-18.Peer-Reviewed Original ResearchConceptsPrimary careAddiction medicineDrug useAddiction treatmentElectronic MEDLINE searchSubstance usePrimary care providersUse of pharmacotherapyCare of patientsInitial reviewSubstance use disordersMental health harmsDrugs of abuseUnhealthy alcoholTreatment of addictionMedical complicationsOutpatient settingMEDLINE searchCare providersUse disordersGeneralist cliniciansBrief interventionGeneralist settingsMedical carePotential articles
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounselingCurrent and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals
Tetrault JM, Fiellin DA. Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals. Drugs 2012, 72: 217-228. PMID: 22235870, PMCID: PMC3701303, DOI: 10.2165/11597520-000000000-00000.Commentaries, Editorials and LettersMeSH KeywordsAnalgesics, OpioidHumansNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid dependenceMaintenance treatmentDrug useHepatitis C virus transmissionOpioid agonist maintenanceOpioid agonist medicationsPotential pharmacological treatment optionsC virus transmissionPharmacological treatment optionsInjection drug useOpioid-dependent individualsDirect healthcare costsIllicit opioid usersHIV risk behaviorsGlobal economic burdenIllicit drug useTerms of HIVSustained-release formulationMaintenance therapyAgonist medicationsOpioid antagonistAgonist maintenanceTreatment optionsOpioid usersImproved outcomes
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence